Abbott Submits Applications for PGx Cancer Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abbott today said that it has completed submissions in the US and Japan for a molecular diagnostic test to detect abnormal gene rearrangements in non-small cell lung cancer tumors.

The test uses fluorescence in situ hybridization technology and has been developed to detect rearrangements in the 2p23 chromosome of the ALK gene. Abbott said that these abnormalities have been implicated in the development of NSCLC, lymphoma, and neuroblastoma.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.